Tomas Uher1, Eva Havrdova1, Lukas Sobisek2, Jan Krasensky3, Manuela Vaneckova3, Zdenek Seidl3, Michaela Tyblova1, Deepa Ramasamy4, Robert Zivadinov5, Dana Horakova1. 1. Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. 2. Department of Statistics and Probability, University of Economics in Prague, Prague, Czech Republic. 3. Department of Radiology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. 4. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA. 5. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA/MR Imaging Clinical Translational Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
Abstract
BACKGROUND: No evidence of disease activity (NEDA) has been proposed as a new treatment goal in multiple sclerosis (MS). NEDA-3 status is defined as the absence of magnetic resonance imaging (MRI; new/enlarging/enhancing lesions and increased whole brain volume loss in NEDA-4) and clinical disease activity. OBJECTIVES: To investigate the persistence of NEDA status over long-term follow-up in MS patients treated with weekly intramuscular interferon beta-1a. METHODS: We included 192 patients after the first demyelinating event suggestive of MS, that is, clinically isolated syndrome (CIS) and 162 relapsing-remitting MS (RRMS) patients. RESULTS: NEDA-3 status was observed in 40.1% of CIS and 20.4% of RRMS patients after 1 year. After 4 years, 10.1% of CIS patients had NEDA-3 status. After 10 years, none of the RRMS patients had NEDA-3 status. Only 4.6% of CIS and 1.0% of RRMS patients maintained NEDA-4 status after 4 years. Loss of NEDA-3 status after the first year was associated with a higher risk of disability progression (hazard ratio (HR) = 2.3-4.0; p = 0.005-0.03) over 6 years. CONCLUSIONS: Despite intramuscular interferon beta-1a treatment, loss of NEDA status occurred in the vast majority of individuals. Loss of NEDA status during the first year was associated with disability progression over long-term follow-up; however, specificity for individual patient was low.
BACKGROUND: No evidence of disease activity (NEDA) has been proposed as a new treatment goal in multiple sclerosis (MS). NEDA-3 status is defined as the absence of magnetic resonance imaging (MRI; new/enlarging/enhancing lesions and increased whole brain volume loss in NEDA-4) and clinical disease activity. OBJECTIVES: To investigate the persistence of NEDA status over long-term follow-up in MS patients treated with weekly intramuscular interferon beta-1a. METHODS: We included 192 patients after the first demyelinating event suggestive of MS, that is, clinically isolated syndrome (CIS) and 162 relapsing-remitting MS (RRMS) patients. RESULTS:NEDA-3 status was observed in 40.1% of CIS and 20.4% of RRMS patients after 1 year. After 4 years, 10.1% of CIS patients had NEDA-3 status. After 10 years, none of the RRMS patients had NEDA-3 status. Only 4.6% of CIS and 1.0% of RRMS patients maintained NEDA-4 status after 4 years. Loss of NEDA-3 status after the first year was associated with a higher risk of disability progression (hazard ratio (HR) = 2.3-4.0; p = 0.005-0.03) over 6 years. CONCLUSIONS: Despite intramuscular interferon beta-1a treatment, loss of NEDA status occurred in the vast majority of individuals. Loss of NEDA status during the first year was associated with disability progression over long-term follow-up; however, specificity for individual patient was low.
Entities:
Keywords:
Multiple sclerosis; brain atrophy; disability; interferons; magnetic resonance imaging; no evidence of disease activity
Authors: Eva Havrdová; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Hans-Peter Hartung; Ludwig Kappos; Fred Lublin; Krzysztof Selmaj; Anthony Traboulsee; Shibeshih Belachew; Iain Bennett; Regine Buffels; Hideki Garren; Jian Han; Laura Julian; Julie Napieralski; Stephen L Hauser; Gavin Giovannoni Journal: Mult Scler J Exp Transl Clin Date: 2018-03-12
Authors: Tjalf Ziemssen; Ann D Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M J Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A Singer Journal: CNS Drugs Date: 2020-09 Impact factor: 5.749
Authors: Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Fritz Leutmezer; Paulus Rommer; Sebastian Wurth; Anne Zinganell; Tobias Zrzavy; Florian Deisenhammer; Thomas Berger Journal: Eur J Neurol Date: 2021-04-02 Impact factor: 6.089
Authors: Jarmila Szilasiova; Pavol Mikula; Jaroslav Rosenberger; Miriam Fedicova; Peter Urban; Lydia Frigova; Marianna Vitkova; Zuzana Gdovinova; Jozef Hanes; Eva Stevens Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2021-06-01 Impact factor: 1.648